Clinical trials: Head and Neck Disorder
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876…
- Conditions
- Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
- Trial name
- NCT04881045
- Testing
- PF-07257876
- Where
- 43 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Pfizer
Nasopharyngeal Carcinoma (NPC)
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
This Phase II study is a clinical trial exploring the efficacy and safety of BL-B01D1 with or without PD-1 monoclonal antibody in patients with high-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07797881
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT07431281
- Testing
- Sonesitatug vedotin, Rilvegostomig, Nivolumab
- Where
- 314 sites in United States, Australia and 22 more
- Volunteers
- 2,130 people
- Sponsor
- AstraZeneca
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Nasopharyngeal Carcinoma
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.
- Trial name
- NCT02328261
- Testing
- Icotinib
- Volunteers
- 66 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Chemoradiotherapy-Induced Severe Oral Mucositis
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.
This study is being performed to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who are being treated with…
- Trial name
- VOICE (NCT04648020)
- Testing
- Clonidine HCl Mucoadhesive Buccal Tablet
- Where
- 74 sites in United States, France and 3 more
- Volunteers
- 190 people
- Sponsor
- Monopar Therapeutics
High-grade Dysplasia in Barrett Esophagus, Non Small Cell Lung Cancer
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Photodynamic therapy (PDT) uses a combination of a drug, porfimer sodium, and a light from a non heated laser. The activation of the drug is done by illuminating abnormal areas using a fiber optic device.
- Conditions
- High-grade Dysplasia in Barrett Esophagus, Non Small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT01256203
- Testing
- Solar Protection Formula SPF® 60, Photobiological testing
- Sponsor
- Pinnacle Biologics Inc.
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Anaplastic Thyroid Cancer
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
- Trial name
- FACT (NCT00507429)
- Testing
- CA4P, paclitaxel, carboplatin
- Where
- 41 sites in United States, Belarus and 10 more
- Volunteers
- 80 people
- Sponsor
- Mateon Therapeutics
Lung Cancer, Breast Cancer
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced…
- Conditions
- Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- NCT00096707
- Testing
- 2-deoxy-D-glucose (2DG)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Threshold Pharmaceuticals
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients…
- Trial name
- NCT02319044
- Testing
- MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab
- Where
- 125 sites in United States, Australia and 13 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT03122548
- Testing
- CRS-207, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Aduro Biotech, Inc.
Non Small Cell Lung Cancer, Cutaneous Melanoma
RTX-224 Monotherapy in Patients With Solid Tumors
This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT05219578
- Testing
- RTX-224
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Rubius Therapeutics
Adult Solid Tumor
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in…
- Trial name
- NCT04892043
- Testing
- SQZ-AAC-HPV, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- SQZ Biotechnologies
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Melanoma (Skin), Squamous Cell Carcinoma of the Skin
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.
- Conditions
- Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic
- Trial name
- NCT03291002
- Testing
- CV8102, CV8102 + anti-PD-1 therapy
- Where
- 22 sites in Austria, France and 3 more
- Volunteers
- 98 people
- Sponsor
- CureVac
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.